Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model

Viruses(2022)10.3390/v14102268Source: DataRank Database

Comparative Pharmacokinetics of a Dual Inhibitor of HIV-1, NBD-14189, in Rats and Dogs with a Proof-of-Concept Evaluation of Antiviral Potency in SCID-hu Mouse Model is a research paper published in Viruses (2022). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 0.07)OA: goldTopics (58)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Francesca Curreli,Stephen Horrigan ORCID,Andrea Altieri ORCID,Alexander V. Kurkin ORCID,Asim K. Debnath ORCID

Live enrichment

PubMed:36298823 PMC:PMC9611370 OpenAlex:https://openalex.org/W4306404306

NIH

Grant: R01 AI104416

NIH

Grant: HHSN272201400002C

National Institutes of Health

Grant: 5R01AI104416-02

Design of inhibitors targeted to the CD4 binding site on HIV-1 gp120

FWCI

0.07

Citation Percentile

0.4%

Citation Trend

2022

goldLicense: cc-by

journalhttps://www.mdpi.com/1999-4915/14/10/2268/pdf?version=1665905957

GOLDhttps://www.mdpi.com/1999-4915/14/10/2268/pdf?version=1665905957

publisherhttps://www.mdpi.com/1999-4915/14/10/2268/pdf?version=1665905957

publisherhttps://www.mdpi.com/1999-4915/14/10/2268/pdf

journalhttps://doi.org/10.3390/v14102268

Fields of Study

HIV Research and TreatmentHIV/AIDS drug development and treatmentImmune Cell Function and InteractionMedicineChemistry0301 basic medicine0303 health sciences03 medical and health sciences

MeSH Terms

AnimalsDisease Models, AnimalDogsHIV SeropositivityHumansHIV-1HIV InfectionsMice, SCIDAnti-HIV AgentsMiceRats

Keywords

PharmacokineticsPharmacologyIn vivoBioavailabilityPotencyReverse transcriptaseReverse-transcriptase inhibitorToxicityAntagonistHuman immunodeficiency virus (HIV)BiologyChemistryIn vitroVirologyMedicineViral loadInternal medicineBiochemistryAntiretroviral therapyReceptorHuman immunodeficiency virus type 1 (HIV-1)Dual InhibitorsPharmacokinetics (Pk)Hiv-1 Gp120 AntagonistScid-hu Mouse ModelAnti-HIV AgentsHIV InfectionsMice, SCIDMicrobiologyQR1-502ArticleRatsMiceDisease Models, AnimalDogsHIV SeropositivityHIV-1HumansAnimals

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being